Galderma has announced the expansion of Alastin’s presence in Japan and the Asia-Pacific region. The premium regenerative skincare brand has already entered the Taiwan market, is preparing for launch in Japan, and has also received the necessary approvals to begin sales in Singapore and South Korea.

The company plans to introduce Alastin in Singapore in September 2026 and in South Korea in November. The expansion follows the brand’s earlier launches in China and Australia and is expected to strengthen Galderma’s position in one of the most dynamic regions of the global professional skincare and aesthetic medicine market.

Galderma expands its regenerative skincare segment

Alastin is positioned as professional skincare designed not only for daily use, but also to support the skin before and after aesthetic procedures. Galderma links the growing interest in such products to the spread of minimally invasive techniques, increased attention to skin quality, and demand for comprehensive programs that combine procedures with properly selected at-home care.

The company notes that today’s patients increasingly expect more from cosmetics than just superficial hydration or a short-term visual effect. They are looking for products that can support skin recovery, resilience, and long-term quality, particularly after laser, energy-based, and injectable procedures.

It is in this context that Galderma is developing Alastin as a separate category that complements its injectable aesthetics portfolio. The brand is intended to cover different stages of the aesthetic journey: pre-procedure preparation, the recovery period, and ongoing daily care.

What is TriHex technology

A key component of some Alastin products is the patented peptide-based TriHex Technology. According to the company, it combines ingredients that help clear the extracellular matrix of damaged collagen and elastin fragments while simultaneously supporting the formation of new structural proteins.

This dual mechanism has become the basis for Alastin’s positioning in the regenerative skincare category. It is not about replacing the skin’s natural processes, but about creating conditions that, according to the brand, can support its own ability to renew and recover.

The product Restorative Skin Complex uses the next generation of the technology, TriHex+‌. The company reports that it additionally supports the natural production of high-molecular-weight hyaluronic acid, as well as processes associated with the formation of collagen and elastin.

Which Alastin products are entering new markets

For Japan and other countries in the region, Galderma has assembled a portfolio of nine products. It includes products for use in connection with aesthetic procedures, specialized serums, and daily skincare products.

  • Skin Nectar – a TriHex Technology product developed to support the skin before and after procedures.
  • INhance – a post-procedure care product intended to help skin recovery and support the visible results of procedures.
  • Restorative Skin Complex with TriHex+‌ – a comprehensive product designed to support the renewal of collagen, elastin, and natural hyaluronic acid.
  • Restorative Eye Complex – eye area skincare with TriHex technology.
  • Restorative Neck Complex – specialized care for the skin of the neck and décolleté.
  • C-RADICAL Defense – an antioxidant serum to protect the skin from external factors.
  • A-LUMINATE Brightening Serum – a serum aimed at reducing the appearance of pigmentation and evening out skin tone.
  • HA IMMERSE Serum – a moisturizing serum focused on supporting hydration.
  • Ultra Nourishing Moisturizer – a nourishing moisturizing product with TriHex Technology.

Thus, Galderma is bringing not just one flagship product to new markets, but a structured skincare system. It addresses both specific concerns—pigmentation, dehydration, care for the eye area or neck—and the broader goal of supporting the skin during the period of aesthetic procedures.

Care before and after aesthetic procedures

One of Alastin’s main areas of focus is so-called peri-procedural care—the use of specially selected products before a procedure and during the recovery period. Galderma states that the brand’s products can be used alongside in-demand energy-based and injectable methods.

For the professional market, this is an important step, as skincare is gradually no longer perceived only as a separate at-home stage. Brands are increasingly building full programs in which cosmetics are meant to prepare the skin for intervention, support it during recovery, and help maintain skin quality between procedures.

At the same time, products for home use do not replace the procedures themselves and do not guarantee the same result for every patient. Their role is to support the skin’s condition and complement a professional program, which should be determined by a specialist based on the type of procedure and the individual tissue response.

Why Galderma is betting on Asia

The company describes Japan and the Asia-Pacific region as one of the key directions for future growth. The medical aesthetics market is developing rapidly there, minimally invasive procedures are spreading, and consumers traditionally pay significant attention to multi-step care and skin quality.

The launch of Alastin also aligns with Galderma’s broader strategy, which combines injectable aesthetics, dermatological skincare, and therapeutic dermatology. After expanding the Restylane portfolio, the company is strengthening another area: professional products that can be used alongside procedures and in between them. More details about the company’s previous portfolio update can be found in the article about the new Restylane syringe.

Galderma also pays particular attention to current shifts in patient demand. Among them, the company cites interest in skin longevity, care during age-related and hormonal changes, as well as skin support after rapid weight loss. In this model, Alastin is intended to become the link between regular at-home care and professional aesthetic correction.

Clinical positioning of Alastin

According to Galderma, Alastin’s scientific base includes more than 60 international dermatology publications, and the brand’s technologies are protected by more than 25 granted patents. The company describes Alastin as one of the most extensively researched professional skincare brands.

At the same time, most of the characteristics and expected results in the press release are presented by the manufacturer itself. When evaluating the products, specialists should take into account the specific formula of the product, its protocol of use, the type of procedure performed, and the quality of independent clinical data for the relevant indication.

For the market, the launch of Alastin in new countries is primarily notable as a continuation of the convergence between professional cosmetics and aesthetic medicine. Large dermatology companies are increasingly offering not individual procedures or products, but entire ecosystems that accompany the patient through different stages of skincare.

About Galderma

Galderma is an international dermatology company present in approximately 90 countries. Its portfolio covers injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company was founded in 1981 and develops such brands and areas as Restylane, Sculptra, Dysport, Alastin, Cetaphil, and therapeutic dermatology solutions.